In a report released today, Amit Hazan from Citigroup maintained a Sell rating on Edwards Lifesciences (NYSE: EW), with a price target of $118. The company’s shares opened today at $142.57.
According to TipRanks.com, Hazan is a 4-star analyst with an average return of 9.8% and a 58.1% success rate. Hazan covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Intuitive Surgical.
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $159.80, which is a 12.1% upside from current levels. In a report issued on October 15, Barclays also initiated coverage with a Sell rating on the stock with a $143 price target.
.
See today’s analyst top recommended stocks >>
Based on Edwards Lifesciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $226 million. In comparison, last year the company had a net profit of $170 million.
Based on the recent corporate insider activity of 108 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.
